Based on data from 909 patients, the terminal half-life of<unk>  is 26.7 days and steady-state concentrations were reached by 12 weeks when administered at 3 mg/kg every 2 weeks. Age, gender, race, baseline LDH, PD-L1 expression, tumor type, tumor size, renal impairment, and mild hepatic impairment do not affect clearance of the drug.
Nivolumab
Pembrolizumab
Risankizumab
Lirentelimab
Icotinib
Bamlanivimab/etesevimab
Obiltoxaximab
Daratumumab